Tel Aviv

REEFER Token Signs Exclusive Agreement with Cannabis AI Pioneer VisiCann To Be Exclusive Seed to Sale NFT Partner

Retrieved on: 
Thursday, March 17, 2022
Decentraland, Crypto.com, Smoke, Metaverse, Famous Smoke Shop, Cannabinoid, Sale, Vape shop, Non-fungible token, Growth, TEL, THC, Weed Wars, Tel Aviv, Tobacco, REEFER, Ecosystem, CEO, NFT, Cannabis, Artificial intelligence, Industry, Technology, Barbary Coast cannabis lounge, Friction, GREEN, Index, Telegraphy, AI, Partnership, Cryptocurrency, Coinbase, Restaurant, Crypto, Green

VisiCann is a pioneer in developing and applying the world's most advanced AI technology for cannabis and hemp extraction

Key Points: 
  • VisiCann will be REEFER Token's exclusive partner for seed to sale NFTs that will launch with growers and brands in the near future.
  • REEFER Token founding team commented, "The REEFER Token team is very excited to enter into an exclusive partnership with VisiCann.
  • They are a great partner for us to really solidify REEFER Token as a leader in seed to sale technology.
  • REEFER Token ($REEFER) is Setting a New Industry Standard on how Legal Dispensaries, Smoke Shops, Vape Shops, Cannabis Lounges, Restaurants and Gamers Interact.

Matan Yemini is recognized by Continental Who's Who

Retrieved on: 
Friday, January 28, 2022
Diamond, Fertility preservation, Intracytoplasmic sperm injection, Patient, Indian Diamond Institute, Weizmann Institute of Science, Tel Aviv, Distinguishing, Kaplan Medical Center, Physician, Program, ICSI, Continental, Embryology, Gynaecology, Male, Research, Laboratory, Reproduction, Medicine, Reproductive medicine, Medical school, Infertility, IVF, Pregnancy, Paola Lattus, Time, Division, Leonard M. Miller School of Medicine, Multimedia, Private practice, GLMA, Partner, Menopause, Birth control, Medical device, Obstetrics, Diagnosis

MILBURN, N.J., Jan. 28, 2022 /PRNewswire/ -- Matan Yemini is being recognized by Continental Who's Who as a Distinguished Infertility Specialist in the Medical field and in acknowledgment of his work at Diamond Institute for Infertility and Menopause.

Key Points: 
  • MILBURN, N.J., Jan. 28, 2022 /PRNewswire/ -- Matan Yemini is being recognized by Continental Who's Who as a Distinguished Infertility Specialist in the Medical field and in acknowledgment of his work at Diamond Institute for Infertility and Menopause.
  • Dr. Yemini is one of two physicians at the Diamond Institute for Infertility and Menopause.
  • Dr. Yemini first attended Jerusalem's Hadassah Hebrew University School of Medicine, graduating in 1978.
  • During that time, Dr. Yemini furthered his training with Reproductive Endocrinology at Kaplan Medical Center's Division of Reproductive Medicine.

Introducing Blitzionaire: The First Play to Earn NFTs Trading Game

Retrieved on: 
Thursday, December 9, 2021
Bitcoin, Veteran, Research, GLOBE, COO, Financial technology, PVP, NFT, TEL, Online gambling

TEL AVIV, Israel, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Playnance Ltd., developer and publisher of financial games, announced the launch of their new play to earn game, Blitzionaire .

Key Points: 
  • TEL AVIV, Israel, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Playnance Ltd., developer and publisher of financial games, announced the launch of their new play to earn game, Blitzionaire .
  • The new game, Blitzionaire, is a social player vs. player game, on market predictions, all in real time.
  • Upon winning, players have the opportunity to buy with their virtual free coins, real Blitzdog NFTs.
  • "Blitzionaire was at first a social trading game, the decision to make it a play to earn NFT game was simply genius" - Yaniv Baruch, COO.

IDB Bank Welcomes Salvador Palma

Retrieved on: 
Thursday, December 9, 2021
Principal, Architecture, GLOBE, Technology, IDB, Leadership, IDB Bank, Food, CEO, Industry, Eve (name), Israel, Biron, Marco Polo, Partner, Solution, Compliance, Creative industries

New York, NY, Dec. 09, 2021 (GLOBE NEWSWIRE) -- IDB Bank is excited to welcome Salvador Palma Chava as the new President of IDB Capital.

Key Points: 
  • New York, NY, Dec. 09, 2021 (GLOBE NEWSWIRE) -- IDB Bank is excited to welcome Salvador Palma Chava as the new President of IDB Capital.
  • In his new role, he will report directly to IDB Bank President and CEO, Ziv Biron.
  • With over 70 years of experience, IDB Bank provides private banking and commercial banking solutions to its clients in healthcare, real estate, apparel, food and beverage, high-tech and not-for-profit sectors.
  • IDB is a New York State chartered bank and wholly owned subsidiary of Israel Discount Bank, Ltd., one of Israels leading financial institutions.

Purple Biotech Appoints Senior Business Development Executive Fabien Sebille as Chief Business Officer

Retrieved on: 
Thursday, December 9, 2021
Transfer, U.S. Securities and Exchange Commission, CM24, Pancreatic cancer, STAT3, State, Company, Forward-looking statement, Business development, SEC, University technology transfer offices, GLOBE, Therapy, University of Nantes, Celecoxib, Cancer, Infection, Drug resistance, Intention, Private Securities Litigation Reform Act, Medical Research Council (United Kingdom), PD-1, Drug development, Food, Hypertension, Patient, Nivolumab, Technology transfer, Large-cell lung carcinoma, Head, CEACAM1, Doctor of Philosophy, OSE, University, Patent, FDA, Legislation, Survival, Marketing, SCCHN, Bristol Myers Squibb, Regulation of tobacco by the U.S. Food and Drug Administration, Annual report, Medical Research Council, Imperial College London, Biotechnology, Cetuximab, Risk, Pharmaceutical industry

REHOVOT, Israel, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced the appointment of Fabien Sebille, Ph.D., a senior business development executive with more than 15 years of professional experience in the biotechnology industry, as its Chief Business Officer.

Key Points: 
  • REHOVOT, Israel, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced the appointment of Fabien Sebille, Ph.D., a senior business development executive with more than 15 years of professional experience in the biotechnology industry, as its Chief Business Officer.
  • Previously, Dr. Sebille served as Executive Director of Business Development and in different senior business development positions, at Debiopharm International SA, a Swiss-based privately-held biopharmaceutical company focused on drug development in oncology and infectious diseases.
  • Fabiens deep scientific background, strong understanding of the biotechnology industry and vast business development experience are ideally suited for the newly created role of Chief Business Officer at Purple Biotech, said Mr. Gil Efron, Purple Biotechs President and Chief Financial Officer.
  • We are thrilled to welcome him to the team and look forward to Fabien leading our business development activities.

mPrest Announces Renewal of the First Cloud Hosted Distributed Energy Resource Management System (DERMS) in Australia

Retrieved on: 
Wednesday, December 8, 2021
MPrest Systems, IT infrastructure, American Energy Partners, LP, GLOBE, DER, Asset health management, VPP, Powercor Australia, OT, Virtual power plant, CEO, Industry, Organization, Distributed generation, Partnership, General of the branch, TEL, Electricity, IOT, Water, AHM, AI, City, Electric power industry, Renewable energy

As one of the first grid operators to deploy a DERMS locally in 2020, CitiPower and Powercor selected mPrest to manage its Distributed Energy Resources (DER).

Key Points: 
  • As one of the first grid operators to deploy a DERMS locally in 2020, CitiPower and Powercor selected mPrest to manage its Distributed Energy Resources (DER).
  • CitiPower and Powercors grid supplies power to over 1.2 million residential households and commercial customers in Victoria.
  • mDERMS was deployed using cloud-connected air conditioning controllers, to reduce electricity demands during peak periods for about 100 customers through the Energy Partner Program trial.
  • Our suite of applications revolutionizes the way energy companies, distribution and transmission utilities and energy retailers manage their systems.

Lendstart Is Helping Customers Choose the Best Personal Loans

Retrieved on: 
Tuesday, December 7, 2021
Failure, Risk, Research, APR, APRS, Attention, Credit

Though it is not the same as a personal loan, a mortgage offers marginally higher loans with lower interests to compete with rising house prices .

Key Points: 
  • Though it is not the same as a personal loan, a mortgage offers marginally higher loans with lower interests to compete with rising house prices .
  • However, mortgage advisors are often assigned to clients to help them pick out the best loans but the same luxury is not afforded to those opting for a personal loan.
  • It is one of the most important factors when one is comparing the best personal loans .
  • According to the personal loan advisors at Lendstart, "Never accept a personal loan if you do not know what the repayment terms are.

Sisense Chooses Panorays to Improve Its Third-Party Security Risk Process

Retrieved on: 
Tuesday, December 7, 2021
Cloud, Moneta, Twitter, Risk, GLOBE, Compliance, StepStone Group, CEO, Business intelligence, Organization, Entrepreneurship, Insurance, Intelligence, No, Adoption, LinkedIn, Software as a service, Online shopping, Cryptocurrency

NEW YORK, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Sisense, the leading AI-driven cloud platform for infusing analytics everywhere, has selected Panorays as its third-party security risk management solution.

Key Points: 
  • NEW YORK, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Sisense, the leading AI-driven cloud platform for infusing analytics everywhere, has selected Panorays as its third-party security risk management solution.
  • Prior to using Panorays, Sisense assessed its vendors security using a lengthy manual process.
  • Now, after switching to Panorays, Sisense has seen the immediate impact Panorays has had on daily operations.
  • Read more about why Sisense selected Panorays for its third-party security risk process.

Purple Biotech Announces Initiation of Part 2 of Ongoing Phase 1/2 Clinical Trial Evaluating NT219 for Treatment of Multiple Cancers Supporting Potential Expansion of Clinical Program

Retrieved on: 
Monday, December 6, 2021
Well, Patient, Drug resistance, Part, Cancer, Pancreatic cancer, Cetuximab, Risk, Nivolumab, Head, Annual report, Company, Achievement, Private Securities Litigation Reform Act, Forward-looking statement, Large-cell lung carcinoma, Bristol Myers Squibb, SEC, Legislation, Part Two, NASDAQ, CEACAM1, Survival, Safety, CM24, GLOBE, Marketing, Patent, SCCHN, PD-1, Intention, Drug development, STAT3, Food, Pharmaceutical industry

REHOVOT, Israel, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Purple Biotech (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced the initiation of Part 2 of its ongoing Phase 1/2 clinical trial of NT219, a novel small molecule inhibiting simultaneously IRS1/2 and STAT3, for the treatment of multiple cancers. Part 2 is a dose escalation study of NT219, beginning with 6mg/kg, in combination with the standard dose of cetuximab (ERBITUX®), in patients with recurrent or metastatic squamous cell carcinoma of head and neck cancer (SCCHN) or colorectal adenocarcinoma.

Key Points: 
  • To date, no drug limiting toxicities have been observed in the trial, and NT219 has been found to be well-tolerated with minimal serious adverse events.
  • Additional preliminary efficacy data from Part 1 of the trial is expected to be presented at a medical meeting in the first half of 2022.
  • The advancement of our ongoing Phase 1/2 clinical trial to Part 2 represents an important achievement for our NT-219 clinical development program, said Michael Schickler, Ph.D., Head of Clinical and Regulatory Affairs of Purple Biotech.
  • Purple Biotech Ltd. is a clinical-stage company developing first-in-class therapies by overcoming tumor immune evasion and drug resistance.

Shield Named RegTech Insight Awards – USA’s Best eComms Surveillance Solution

Retrieved on: 
Wednesday, December 1, 2021
Discovery, CEO, Industry, AI, Compliance, Marketing, Human, Solution, Communication, GLOBE, NLP, Organization, Social media, TEL, E-Comm, Privacy, Science and technology in Asia, Tag Team (group), Shield, Financial adviser, Risk management

TEL AVIV, Israel, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Shield , the worlds leading Workplace Intelligence platform for compliance teams, today announced it has been selected to the RegTech Insight Awards USA list for 2022, recognizing established solution providers and innovators, for the Best e-Comms Surveillance Solution category.

Key Points: 
  • TEL AVIV, Israel, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Shield , the worlds leading Workplace Intelligence platform for compliance teams, today announced it has been selected to the RegTech Insight Awards USA list for 2022, recognizing established solution providers and innovators, for the Best e-Comms Surveillance Solution category.
  • The RegTech Insight Awards honors companies that improve the ability for firms in the financial services industry to effectively respond to the evolving and complex regulatory requirements.
  • Were honored to be recognized by such a prestigious organization like the RegTech Insight Awards, alongside some of the worlds leading innovative fintech companies, said Iftach Drori, Head of Marketing and Investor Relations at Shield.
  • We are delighted that our RegTech Insight community of over 35,000 senior regtech specialists has votedShieldas theBest e-Comms Surveillance Solutionin this highly competitive field.Shieldhas proven themselves to be deserving winners and we congratulate them on their success, said Angela Wilbraham, CEO of A-Team Group, which hosts the prestigious RegTech Insight Awards USA.